Can the ACE inhibitor lisinopril be prescribed twice daily?

Can Lisinopril Be Prescribed Twice Daily?

Yes, lisinopril can be prescribed twice daily, and emerging evidence suggests that twice-daily dosing may provide superior blood pressure control compared to once-daily administration of the same total daily dose, though this approach is not the standard FDA-recommended regimen. 1

FDA-Approved Dosing Regimen

• The FDA label for lisinopril specifies once-daily administration as the standard dosing schedule for hypertension, heart failure, and acute myocardial infarction. 1
• For hypertension, the recommended initial dose is 10 mg once daily, with titration to 20–40 mg once daily based on blood pressure response; doses up to 80 mg have been used but do not provide greater antihypertensive effect. 1
• The FDA label does not explicitly recommend or approve twice-daily dosing as a standard regimen. 1

Evidence Supporting Twice-Daily Dosing

Blood Pressure Control

• A 2017 retrospective cohort study demonstrated that lisinopril 20 mg twice daily produced a 10.2/4.3 mmHg greater reduction in systolic/diastolic blood pressure compared to 40 mg once daily (P=0.016 for systolic BP). 2
• The twice-daily regimen achieved blood pressure reductions of 16.5/5.9 mmHg versus 6.2/1.5 mmHg with once-daily dosing in patients previously receiving 20 mg daily. 2

Neurohumoral Effects in Heart Failure

• In patients with mild chronic heart failure, twice-daily lisinopril administration resulted in significantly lower plasma norepinephrine concentrations and a trend toward lower plasma renin activity compared to once-daily dosing of the same total daily dose. 3
• Hemodynamic parameters, renal function, brain natriuretic peptide, and heart rate variability (CVRR) did not differ between regimens, but the neuroendocrine benefits suggest potential advantages of twice-daily dosing in heart failure. 3

Systematic Review Findings

• A 2021 systematic review of six studies comparing once-daily versus twice-daily ACE inhibitor dosing found that twice-daily administration provided similar or greater blood pressure-lowering effects than once-daily dosing. 4
• The review noted that ACE inhibitors' pharmacokinetic and pharmacodynamic properties play an integral role in determining blood pressure outcomes, with no added safety concerns for twice-daily versus once-daily administration. 4

Contradictory Evidence

• A large 2020 retrospective cohort study (11,210 lisinopril patients) found no significant differences in systolic or diastolic blood pressure between twice-daily and once-daily dosing, with absolute differences ranging from -1.8 to 0.7 mmHg for systolic BP and -1.1 to 0.1 mmHg for diastolic BP (all 95% confidence intervals crossed zero). 5
• Lisinopril 10 mg twice daily was associated with increased odds of angioedema compared to 20 mg once daily (odds ratio 2.27,95% CI 1.13–4.58). 5
• Only 7.0% of lisinopril patients in this real-world study were taking twice-daily dosing, and these patients were older with higher comorbidity burdens. 5

Guideline Recommendations for Lisinopril Dosing

• The European Society of Cardiology and American College of Cardiology guidelines recommend once-daily lisinopril dosing as the standard approach, with target doses of 20–35 mg once daily for heart failure and 20–40 mg once daily for hypertension. 6
• When blood pressure remains uncontrolled on maximum once-daily lisinopril (40 mg), guidelines recommend adding a thiazide diuretic (hydrochlorothiazide 12.5–25 mg daily) or a calcium-channel blocker rather than splitting the dose to twice-daily administration. 6
• The ATLAS trial in heart failure demonstrated that high-dose lisinopril (32.5–35 mg daily) reduced death or heart failure hospitalization by 15% compared to low-dose (2.5–5 mg), supporting the use of higher once-daily doses. 6

Practical Clinical Algorithm

When to Consider Twice-Daily Dosing:

1. Inadequate 24-hour blood pressure control on once-daily dosing, particularly if morning blood pressure remains elevated despite adequate evening dosing. 2
2. Heart failure patients who may benefit from more consistent neurohumoral suppression throughout the day. 3
3. Patients with documented end-of-dose blood pressure elevation on ambulatory monitoring. 4

When to Avoid Twice-Daily Dosing:

1. Adherence concerns, as twice-daily regimens reduce medication compliance compared to once-daily dosing. 4
2. Elderly patients or those with multiple comorbidities, who may have increased angioedema risk with twice-daily dosing. 5
3. When combination therapy is an option, as adding a second antihypertensive class (thiazide or calcium-channel blocker) is the guideline-recommended approach for uncontrolled hypertension. 6

Safety Monitoring

• Check serum creatinine and potassium within 1–2 weeks after initiating or changing lisinopril dosing frequency, especially in patients with chronic kidney disease, diabetes, or heart failure. 6
• Monitor for angioedema more closely with twice-daily dosing, particularly at lower individual doses (e.g., 10 mg twice daily), as this may paradoxically increase risk. 5
• An increase in creatinine up to 50% from baseline or to ≤265 µmol/L (≈3 mg/dL) is acceptable; beyond this, dose reduction or discontinuation is required. 6

Common Pitfalls to Avoid

• Do not split to twice-daily dosing before maximizing once-daily dosing to the FDA-approved maximum of 40 mg daily for hypertension. 1
• Do not assume twice-daily dosing is always superior; the largest real-world study showed no benefit and potential harm. 5
• Do not use twice-daily dosing as a substitute for guideline-recommended combination therapy when blood pressure remains uncontrolled on monotherapy. 6
• Do not combine lisinopril with an ARB or direct renin inhibitor, as dual RAAS blockade increases hyperkalemia, syncope, and acute kidney injury risk 2–3-fold without cardiovascular benefit. 6